Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 7:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,124 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Isotonic saline 0.9% Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults

NCT05721287
View directory record Official record
Conditions
Pain, Acute Pain
Interventions
SBS-1000, Placebo
Drug
Lead sponsor
Sparian Biosciences, Inc
Industry
Eligibility
18 Years to 59 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 4 Interventional Results available

Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections for Knee Osteoarthritis

NCT02576249
View directory record Official record
Conditions
Osteoarthritis
Interventions
Ropivacaine, Normal saline, Methylprednisolone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Crizanlizumab for Treating COVID-19 Vasculopathy

NCT04435184
View directory record Official record
Conditions
COVID-19
Interventions
Crizanlizumab, 0.9% saline
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 3, 2026, 7:29 PM EDT
Terminated Phase 4 Interventional

Fascia Iliaca Block for Post-Operative Pain Control After Total Hip Arthroplasty

NCT02299271
View directory record Official record
Conditions
Osteoarthritis of the Hip
Interventions
Ropivacaine, Saline
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 3, 2026, 7:29 PM EDT
Recruiting Phase 1 Interventional

Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury

NCT07384052
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Regular Insulin, 0.9 % Normal Saline
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Leprosy Skin Test Antigens Trial

NCT00128193
View directory record Official record
Conditions
Leprosy
Interventions
Tuberculin, Purified Protein Derivative, MLSA-LAM, MLCwA, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

NCT04670614
View directory record Official record
Conditions
Post-operative Surgical Pain
Interventions
Nerve Block with ropivicaine 0.5% Injectable Solution, Nerve Block with Placebo sham control of 0.9% Normal Saline
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis

NCT02761993
View directory record Official record
Conditions
Periodontal Disease
Interventions
ST266, Saline (0.9% NaCl)
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years to 85 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Indianapolis, Indiana • Cambridge, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Oct 3, 2026, 7:29 PM EDT
Terminated Phase 1 Interventional

Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates

NCT01158729
View directory record Official record
Conditions
Postoperative Hemorrhage
Interventions
Antithrombin (Recombinant), Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
4 Days to 30 Days
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 3, 2026, 7:29 PM EDT
Withdrawn Phase 2 Interventional

Anakinra, COVID-19, Cytokine Storm

NCT04603742
View directory record Official record
Conditions
Covid19, Cytokine Storm, Mechanical Ventilation Complication
Interventions
Anakinra, 0.9% Saline
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Percutaneous Lumbar Epidural Adhesiolysis and Neurolysis on Low Back Pain

NCT00370994
View directory record Official record
Conditions
Low Back Pain
Interventions
Caudal epidural injection, Percutaneous adhesiolysis
Procedure
Lead sponsor
Pain Management Center of Paducah
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Paducah, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

NCT01264783
View directory record Official record
Conditions
Myocardial Infarct
Interventions
RNS60, Placebo
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 3, 2026, 7:29 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Endothelial Hyperpolarization in Humans

NCT00166166
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Tetraethylammonium (TEA), L-NG-monomethyl Arginine (L-NMMA), Bradykinin, Sodium nitroprusside, Acetylcholine, Saline, Fluconazole
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Antegrade Versus Retrograde IV for Blood Draws

NCT03533777
View directory record Official record
Conditions
There is no Focus on Any Specific Condition
Interventions
Peripheral intravenous catheter placement, Blood draw, Peripheral intravenous catheter, To keep open (TKO) infusion of 0.9% normal saline
Procedure · Other · Device + 1 more
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 90 Years
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients

NCT02035605
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
ALN-AT3SC, Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 3, 2026, 7:29 PM EDT
Not yet recruiting Phase 2 Interventional

Visual Instillation of Sphenopalatine-block Intervention for ONgoing Migraine

NCT07764783
View directory record Official record
Conditions
Migraine, Facial Pain or Pressure, Headache
Interventions
Topical solution of 4% lidocaine, Saline 0.9%
Drug
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 1Phase 2 Interventional

Joint Injections for Osteoarthritic Knee Pain

NCT00085722
View directory record Official record
Conditions
Osteoarthritis
Interventions
Dextrose Prolotherapy, Saline Prolotherapy, At-home physical therapy exercise group
Procedure · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
40 Years to 70 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 3, 2026, 7:29 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)

NCT06685757
View directory record Official record
Conditions
Antibody-mediated Rejection
Interventions
Felzartamab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 75 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
Los Angeles, California • Orange, California • San Bernardino, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
14
States / cities
Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2019 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 4 Interventional Results available

Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation

NCT03133767
View directory record Official record
Conditions
Fluid Loss, Symptom Complex, Triple, Emergencies
Interventions
Lactated Ringer Solution, Normal Saline 0.9% Infusion Solution Bag
Drug
Lead sponsor
Nicholas M Mohr
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 3, 2026, 7:29 PM EDT
Recruiting Phase 3 Interventional

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

NCT06807437
View directory record Official record
Conditions
Pancreatic Carcinoma, Pancreatic Neoplasm
Interventions
Biospecimen Collection, Distal Pancreatectomy, Lanreotide, Questionnaire Administration, Saline
Procedure · Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
118
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Clazakizumab (Anti-Interleukin 6 (IL-6) Monoclonal) Compared to Placebo for Coronavirus Disease 2019 (COVID-19)

NCT04348500
View directory record Official record
Conditions
COVID-19
Interventions
Clazakizumab
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 2 Interventional Results available

Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis

NCT01753076
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Ozanezumab, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • Syracuse, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2017 · Synced Oct 3, 2026, 7:29 PM EDT
Completed Phase 4 Interventional Results available

Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis

NCT01482091
View directory record Official record
Conditions
Anemia, Sickle Cell, Pain
Interventions
Fentanyl Citrate, Normal Saline
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
3 Years to 21 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 3, 2026, 7:29 PM EDT